Novel drug shows promise in boosting survival for pancreatic cancer patients
A novel pill has significantly extended the lives of patients with advanced pancreatic cancer, researchers reported Sunday, raising hopes of improved treatments for one of the most lethal forms of cancer, reports BritPanorama.
The medication, named daraxonrasib, functions by inhibiting a mutated protein responsible for tumor growth in over 90% of pancreatic cancer cases — a protein that has evaded targeted treatment for decades. In a study involving 500 patients whose metastatic cancer had resisted previous therapies, those receiving the daily pills experienced nearly double the survival time compared to those treated with conventional chemotherapy. The findings were published in the New England Journal of Medicine and presented at the American Society for Clinical Oncology meeting in Chicago.
Patients on daraxonrasib lived for a median of 13.2 months, compared to 6.7 months for chemotherapy recipients. Dr. Zev Wainberg from the University of California, Los Angeles, who led the study, pointed out that while the improvement might seem modest, it represents the first significant advancement over standard chemotherapy treatments.
Notably, the pills resulted in fewer severe side effects, allowing patients to stay on treatment longer, which in turn may enhance survival outcomes as further data becomes available. Dr. Wainberg remarked on the unusual finding of patients remaining on the treatment due to its perceived benefits, allowing for the potential for the survival gap to widen as researchers continue monitoring responses.
Dr. Brian Wolpin from the Dana-Farber Cancer Institute referred to these results as potentially setting a “new standard of care” for patients with previously treated metastatic pancreatic cancer. He mentioned that ongoing research may explore applications of daraxonrasib at earlier stages of the disease to ascertain if it could assist in qualifying more patients for surgical intervention.
The side effects noted to affect the usage of daraxonrasib included severe skin rashes and mouth sores. The study, funded by Revolution Medicines, has prompted the Food and Drug Administration to initiate an expedited review process for the drug, which is also allowing “expanded access” for qualifying patients. The drug has drawn public attention following accounts from former U.S. Senator Ben Sasse, who discussed his positive experiences with the treatment.
Pancreatic cancer remains one of the deadliest types, largely because it is challenging to detect early. The American Cancer Society estimates around 67,000 new cases in the U.S. for this year, with over 52,000 deaths anticipated. The overall five-year survival rate stands at a mere 13%. In contrast to many other cancers, pancreatic cancer has lacked a wide variety of effective treatment options.
Experts not involved in this new research expressed cautious optimism, suggesting that this development could represent a pivotal moment in the ongoing search for novel treatments, with numerous experimental drugs currently under investigation.
Dr. Wainberg noted that future studies are expected to assess whether daraxonrasib demonstrates improved efficacy across various KRAS mutations, reinforcing the ongoing evolution of treatment for pancreatic cancer.
The complexity of pancreatic cancer treatment underscores a persistent challenge in oncology, yet advancements such as this may light the path toward transformative changes in patient care.
